Combination Strategy of Arsenic Trioxide and its Metabolite For Leukemia Treatment and Modulation of Endoplasmic Reticulum-mediated Hepatotoxicity
The combination strategy of ATO and metabolite can provide valuable references for future reducing clinical dosage of ATO and enhancing medication safety.
Authors
- Yongfang Yao (ORCID: https://orcid.org/0000-0001-6455-1213)
- Q Huang (ORCID: https://orcid.org/0009-0001-0253-5071)
- Ruijie Deng (ORCID: https://orcid.org/0000-0001-9094-124X)
- Y. Liu (ORCID: https://orcid.org/0000-0001-6985-1434)
- W. Ye
- Xianli Xue
- Jue Yang (ORCID: https://orcid.org/0000-0002-6150-8890)
- Qiuhua Liu (ORCID: https://orcid.org/0000-0001-7476-4634)
- Ying Xing (ORCID: https://orcid.org/0009-0007-3024-3627)
- Cheng Lu (ORCID: https://orcid.org/0000-0002-8577-4288)
- Xu Bai (ORCID: https://orcid.org/0000-0003-4877-8383)
Institutions
- Beijing University of Chinese Medicine (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-10-28
- DOI
- https://doi.org/10.21873/anticanres.17815
- Primary Topic
- Retinoids in leukemia and cellular processes
- Type
- article
- Field-Weighted Citation Impact
- 0.00